AbbVie/Genmab’s Epkinly (epcoritamab), meanwhile, is labelled for use in DLBCL patients after two or more systemic therapies, but has also been submitted as a third-line therapy for FL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback